Literature DB >> 23053470

Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease.

Markus Niemann1, Tanja Hartmann, Mehdi Namdar, Frank Breunig, Meinrad Beer, Wolfram Machann, Sebastian Herrmann, Georg Ertl, Christoph Wanner, Frank Weidemann.   

Abstract

BACKGROUND: Morphology and function of Fabry cardiomyopathy has been previously studied by echocardiography and cardiac magnetic resonance (CMR). However, the value of electrocardiography (ECG) in relation to these two techniques remains largely unknown.
METHODS: One hundred fifty genetically confirmed Fabry patients were investigated using a comprehensive clinical workup comprising 12-lead ECG, echocardiography, and CMR.
RESULTS: ECG parameters at rest [PR, P wave, QT, QTc, QT dispersion and time interval from the peak to the end of the T wave (Tpeak to Tend)] were normal in the entire cohort and did not distinguish between males and females or stages of cardiomyopathy. A significant positive correlation was found between left ventricular (LV) mass on CMR and both the QRS duration and the LV Sokolow index, with the highest values in male patients with an advanced cardiomyopathy stage. No prediction of late enhancement on CMR (a sign for replacement fibrosis) was possible by a single ECG parameter. However, the absence of ST or T alterations (in 37 of 38 patients) specifically excluded late enhancement on CMR.
CONCLUSION: Our data in a large cohort of Fabry patients, including all cardiomyopathy stages, show, in contrast to former assumptions, that ECG parameters are not suitable to stage Fabry cardiomoypathy. Most ECG parameters were normal in the complete cohort. However, the absence of ST or T alterations seems to almost exclude late enhancement on CMR in these patients.

Entities:  

Mesh:

Year:  2012        PMID: 23053470     DOI: 10.1007/s10545-012-9540-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  26 in total

1.  The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease.

Authors:  James C Moon; Mary Sheppard; Emma Reed; Phillip Lee; Perry M Elliott; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2006       Impact factor: 5.364

2.  PQ interval in patients with Fabry disease.

Authors:  Mehdi Namdar; Christoph Kampmann; Jan Steffel; Daniel Walder; Johannes Holzmeister; Thomas Felix Lüscher; Rolf Jenni; Firat Duru
Journal:  Am J Cardiol       Date:  2010-03-01       Impact factor: 2.778

3.  The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy.

Authors:  Markus Niemann; Frank Breunig; Meinrad Beer; Sebastian Herrmann; Jörg Strotmann; Kai Hu; Andrea Emmert; Wolfram Voelker; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  Heart       Date:  2010-10-21       Impact factor: 5.994

4.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

5.  A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

Authors:  C M Eng; M Banikazemi; R E Gordon; M Goldman; R Phelps; L Kim; A Gass; J Winston; S Dikman; J T Fallon; S Brodie; C B Stacy; D Mehta; R Parsons; K Norton; M O'Callaghan; R J Desnick
Journal:  Am J Hum Genet       Date:  2001-02-01       Impact factor: 11.025

6.  Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease.

Authors:  J Mehta; N Tuna; J H Moller; R J Desnick
Journal:  Am Heart J       Date:  1977-06       Impact factor: 4.749

7.  Angina in fabry disease reflects coronary small vessel disease.

Authors:  Cristina Chimenti; Emanuela Morgante; Gaetano Tanzilli; Enrico Mangieri; Giuseppe Critelli; Carlo Gaudio; Matteo A Russo; Andrea Frustaci
Journal:  Circ Heart Fail       Date:  2008-09       Impact factor: 8.790

8.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

9.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

10.  Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.

Authors:  Stephen Waldek; Manesh R Patel; Maryam Banikazemi; Roberta Lemay; Philip Lee
Journal:  Genet Med       Date:  2009-11       Impact factor: 8.822

View more
  8 in total

Review 1.  Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.

Authors:  Aleš Linhart; Tomáš Paleček
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

2.  Electrical Changes in Resting, Exercise, and Holter Electrocardiography in Fabry Cardiomyopathy.

Authors:  Johannes Krämer; Peter Nordbeck; Stefan Störk; Christian Ritter; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  JIMD Rep       Date:  2015-10-27

Review 3.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 4.  Fabry disease and its cardiac involvement.

Authors:  Toru Kubo
Journal:  J Gen Fam Med       Date:  2017-05-08

5.  The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.

Authors:  João B Augusto; Nicolas Johner; Dipen Shah; Sabrina Nordin; Kristopher D Knott; Stefania Rosmini; Clement Lau; Mashael Alfarih; Rebecca Hughes; Andreas Seraphim; Ravi Vijapurapu; Anish Bhuva; Linda Lin; Natalia Ojrzyńska; Tarekegn Geberhiwot; Gabriella Captur; Uma Ramaswami; Richard P Steeds; Rebecca Kozor; Derralynn Hughes; James C Moon; Mehdi Namdar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-06-22       Impact factor: 6.875

Review 6.  Electrocardiographic Changes and Arrhythmia in Fabry Disease.

Authors:  Mehdi Namdar
Journal:  Front Cardiovasc Med       Date:  2016-03-24

7.  Natural history of the late-onset phenotype of Fabry disease due to the p.F113L mutation.

Authors:  Olga Azevedo; Miguel F Gago; Gabriel Miltenberger-Miltenyi; Ana Raquel Robles; Maria Antónia Costa; Olga Pereira; Ana Teresa Vide; Gonçalo Castelo Branco; Sónia Simões; Maria José Guimarães; Ana Salgado; Nuno Sousa; Damião Cunha
Journal:  Mol Genet Metab Rep       Date:  2020-02-15

8.  Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease.

Authors:  Matthew Zada; Queenie Lo; Siddharth J Trivedi; Mehmet Harapoz; Anita C Boyd; Kerry Devine; Norman Sadick; Michel C Tchan; Liza Thomas
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.